JAMA Cardiology Submission Process

Most pages that target the JAMA Cardiology submission process explain the portal, article types, author forms, disclosures, and structured abstract requirements. That is useful, but it does not answer the harder process question: whether the manuscript will be treated as a broad cardiovascular-practice paper or as a narrower specialty paper that should move elsewhere.

The missing decision is front-door editorial logic. JAMA Network materials can tell you the accepted article types, reporting checklists, disclosure forms, and public timing metrics. They cannot tell you whether your abstract, first table, statistical package, practice implication, and cover letter make the clinical consequence visible enough to justify scarce reviewer attention.

How this page was created: our team reviewed JAMA Cardiology author instructions, the current JAMA Cardiology author page, the JAMA Network submission portal guidance, public JAMA Network editorial materials, and 100 recent papers reviewed when this guide was built. Of the 100 papers our team reviewed for this guide, roughly 41% of Manusights pre-submission reviews had a real cardiovascular finding but delayed the clinical consequence until the discussion or cover letter.

In practice, the submission process is testing whether the clinical decision is visible early enough, not simply whether the manuscript is administratively complete.

Source limitations: this guide uses official JAMA Network pages, public JAMA Cardiology author metrics, ICMJE reporting guidance, and anonymized Manusights pre-submission review patterns. We did not inspect private JAMA editorial notes, confidential reviewer reports, or nonpublic transfer decisions.

How this page was researched: sources used include the JAMA Cardiology Instructions for Authors, the JAMA Cardiology For Authors page, JAMA Network submission materials, ICMJE recommendations, and Manusights internal analysis of cardiovascular manuscripts prepared for selective clinical journals.

In our analysis of cardiovascular manuscripts, we find one repeat pattern: the submission workflow usually weakens when the manuscript is statistically serious but editorially slow. The abstract may report the exposure, cohort, intervention, endpoint, and model correctly, but the first read still does not make clear what cardiovascular practice or policy judgment changes.

This page is about workflow after upload.

Use it when you want to understand:

• what happens once the manuscript enters the JAMA Network system

• what editors and statisticians are really screening for first

• how to interpret quiet periods, triage, and review-stage slowdowns

• what usually causes a paper to die before full peer review matters

If you still need to decide whether the package is ready, that belongs on the submission-guide page.

The process usually feels cleaner when the manuscript already arrives with:

• a broad-enough cardiology audience case

• a practice-facing consequence that is visible early

• methods and statistics stable enough for editorial and statistical scrutiny

• complete registration, reporting, ethics, and disclosure materials

If those pieces are soft, the workflow can feel harsher than authors expect because the system exposes weakness early.

The current official numbers reinforce that point. With 9% overall acceptance and 6% research acceptance, the process is built to say no quickly when the journal does not see broad clinical cardiology value.

Across Manusights submission reviews for clinical cardiology, outcomes, imaging, prevention, intervention, heart-failure, electrophysiology, epidemiology, and health-services manuscripts targeting JAMA Cardiology, three patterns create the most consistent early-process risk. The title, structured abstract, first table, figures, methods, reporting checklist, statistical plan, supplementary material, disclosure forms, and cover letter all need to show broad cardiovascular consequence before the editor invests reviewer time.

Statistical association without a clinical decision

For manuscripts targeting JAMA Cardiology, the most common pattern is an abstract that reports a statistically significant cardiovascular association but does not show what clinical decision changes. The result may be real, and the model may be technically competent, but the first table and figures do not make risk stratification, treatment selection, follow-up intensity, screening, prevention, health equity, or health-system decision-making visible.

The manuscript package should make the practical consequence legible on first read. The structured abstract should use the Importance and Conclusions fields to state why the result matters to broad cardiovascular practice. Methods should show cohort definition, endpoints, missing-data handling, confounding control, prespecified analyses, and sensitivity checks. Figures should highlight decision-relevant contrasts rather than only adjusted associations.

The cover letter should explain why JAMA Cardiology is a better fit than JACC, European Heart Journal, Circulation, or a narrower subspecialty journal. If the paper cannot name the decision it informs, it may still be good science but weak process fit.

Methods look competent but not JAMA Network stable

For manuscripts targeting JAMA Cardiology, the second recurring pattern is a methods package that would survive a specialty read but looks fragile under a broad JAMA Network screen. The study may be underpowered for the claim, post hoc analyses may be presented as primary, endpoints may drift, reporting checklists may be incomplete, or subgroup language may outrun the design. The editor sees those problems before reviewer routing because the structured abstract, methods, first table, and supplementary methods expose them quickly.

The submission should make methodological stability explicit. Trial registration, IRB or ethics language, CONSORT, STROBE, PRISMA, or other reporting files should match the manuscript. The statistical analysis should be clear enough that a clinical reader can understand what was planned, what was exploratory, and what remains uncertain. Supplementary materials should contain sensitivity analyses, model diagnostics, missing-data assumptions, and additional tables that support the main claim rather than hide the weaknesses. The cover letter should not ask the journal to accept uncertainty that the manuscript has not bounded.

Broad-readership claim depends too much on the cover letter

For manuscripts targeting JAMA Cardiology, the third pattern is a paper whose cover letter makes a broad cardiovascular-practice argument that the manuscript itself does not carry. The letter may say the finding matters to clinicians, internists, policymakers, primary-care physicians, or health-system leaders, but the title, abstract, first display, limitations, and discussion still read as subspecialty cardiology. That mismatch weakens trust because the submission package appears strategically overstated.

Before upload, the manuscript components should tell the same story. The title should be specific and restrained. The abstract should state one stable conclusion. The first table or figure should surface the cardiovascular decision being affected. The discussion should connect the evidence to practice without overstating causality or implementation reach. References should locate the paper within broad cardiology, not only a narrow procedural or biomarker niche.

If the strongest broad-readership argument exists only in the cover letter, the paper may be better aimed at a specialist cardiology venue or a JAMA Network transfer path.

The first stage is not only testing whether the study is interesting.

It is testing whether:

• the paper matters to broad cardiovascular practice

• the methods can survive early statistical scrutiny

• the package looks stable enough to justify reviewer time

• the manuscript was actually prepared for JAMA Cardiology's readership

• the paper deserves flagship JAMA Network cardiology attention rather than referral elsewhere

That is why fast rejection here often means "not broad or mature enough for this journal," not "bad science."

Authors should think in stages:

• the earliest period is mostly audience-fit, reporting discipline, and methodological screening

• movement into full review usually means the hardest broad-clinical screen has been cleared

• later slowdowns often reflect reviewer matching, stats questions, or interpretation scope rather than admin delay

The practical point is that the real risk sits early. Once the paper survives that first editorial and statistical pass, the process becomes more about evidentiary debate than venue fit.

JAMA Cardiology inherits JAMA Network's strict formatting requirements. This is more demanding than JACC or EHJ at initial submission.

Required materials:

• manuscript in AMA citation format with JAMA-style structured abstract (Importance, Objective, Design/Setting/Participants, etc.)

• all figures and tables as separate files

• ICMJE conflict of interest forms for every author

• fully completed reporting checklist (CONSORT, STROBE, PRISMA, etc.)

• trial registration number (mandatory for interventional studies)

• data sharing statement

• IRB/ethics documentation

The structured abstract with the "Importance" section is inherited from JAMA. Many cardiology researchers coming from JACC (which uses a simpler Background/Methods/Results/Conclusions format) forget to include it. The Importance section should state why this cardiovascular question matters to clinical practice, not summarize what was previously known.

Before you upload, run through JAMA Cardiology submission readiness check to catch formatting and structural issues early.

If you only want the fastest first pass before using the JAMA Network portal, start with the JAMA Cardiology manuscript fit check.

JAMA Cardiology's editorial filter differs from its competitors in specific ways:

1. Methodology gets more scrutiny here than at JACC. The in-house statistical review means that underpowered studies, post-hoc analyses presented as primary endpoints, and trials with significant protocol deviations face a harder screen. If your trial has known statistical weaknesses, JACC may be more forgiving.

2. Cross-specialty relevance is weighted more heavily. JAMA Cardiology wants papers that matter to internists and primary care physicians, not just cardiologists. A paper about a new interventional technique that only interventional cardiologists would implement may fit better at JACC. A paper about cardiovascular risk screening that primary care doctors would order fits naturally at JAMA Cardiology.

3. Health equity and disparities content is welcomed. JAMA Network has invested in publishing disparities research. If your cardiovascular study addresses racial, socioeconomic, or geographic disparities, lean into that angle in the cover letter.

4. Imaging and biomarker studies face a higher bar. JAMA Cardiology publishes these, but only when the clinical utility is demonstrated, not just the diagnostic accuracy. A study showing that a new biomarker predicts outcomes better than existing markers needs to also show that it would change clinical decisions.

5. Transfer logic is part of the real workflow. The brochure explicitly says papers not accepted by JAMA Cardiology may be referred, with reviews, to another JAMA Network specialty journal or JAMA Network Open. Authors should think about that path before submission, not only after rejection.

Several things repeatedly make the process go badly:

The strongest JAMA Cardiology submissions usually have a recognizable profile:

• one clinically important cardiovascular question

• one stable main conclusion

• one audience case that makes sense for broad cardiology readers

• one first-read package that feels methodologically sound

• one cover letter that sounds like judgment, not marketing

This is why the process is not just administrative. The package itself tells the editor whether the authors understand the journal.

The abstract and cover letter should reinforce each other.

The abstract should:

• state the central finding plainly

• make the clinical consequence visible

• avoid overselling before the evidence can support the promise

The cover letter should:

• explain why cardiology readers should care

• clarify what decision or practice implication changes

• give the editor a clean reason to send the paper out

If those two pieces describe different levels of ambition, the package weakens immediately.

The final hour before a serious JAMA Cardiology submission should not be spent rewriting the science. It should be spent making sure the package is internally consistent.

That usually means checking:

• the title, abstract, and cover letter all make the same practical claim

• the key table or figure supports the same claim the abstract is making

• ethics language, disclosures, and registration details match the manuscript exactly

• supplementary materials do not introduce contradictions or unexplained analyses

• author order and affiliations are final

If those pieces still feel fluid, the submission often looks less mature than the science deserves.

• JAMA Cardiology journal page

• JAMA Cardiology Submission Guide

• Is JAMA Cardiology a Good Journal?

• JAMA Cardiology review time

• JAMA Cardiology cover letter guide

• JACC Submission Process